|Mr. Brady James Granier||Pres, CEO & Director||210k||N/A||1972|
|Ms. Lourdes Felix||CFO, COO & Director||199.05k||N/A||1968|
|Dr. Balbir S. Brar||Sr. VP of Drug Devel.||N/A||N/A||1937|
|Dr. George N. Fallieras||Medical Consultant||N/A||N/A||N/A|
BioCorRx Inc., through its subsidiaries, provides alcoholism and opioid addiction treatment program for use in rehabilitation and treatment centers in the United States. The company distributes and licenses BioCorRx recovery program, a medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant. It is also developing BICX101, an injectable naltrexone product; and BICX102, an implantable naltrexone implant for the treatment of alcohol and opioid addiction. The company distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is headquartered in Anaheim, California.
BioCorRx Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.